ClinicalTrials.gg
CompletedNCT04209855MIRASOLUpdated Aug 27, 2025Results posted

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

A Phase 3 interventional study of Mirvetuximab Soravtansine and Paclitaxel in Epithelial Ovarian Cancer, Peritoneal Cancer and Fallopian Tube Cancer, sponsored by AbbVie. Completed at 214 sites in 21 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-27.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
453
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 500 studies in Carcinoma, Ovarian Epithelial with a site in United States — 29 open to participants now, 50 under way, 8 of them phase 3. Carcinoma, Ovarian Epithelial · United States.

Enrollment
25th of 381
453 · median 35
Started
2019
with 7 others
Phase 3
37 of 500
5 open now
Registered
431st of 500
by date

Among the 500 studies in Carcinoma, Ovarian Epithelial with a site in United States, this one is the 25th largest by enrollment of the 381 interventional ones that give a count, is one of 8 that started in 2019, is one of 37 in phase 3, and was the 431st registered.

Carcinoma, Ovarian Epithelial

798 studies on the registry are indexed under Carcinoma, Ovarian Epithelial; 102 are open to participants now.

Browse Carcinoma, Ovarian Epithelial studies →

Open to participants now

29 of the 500 studies in Carcinoma, Ovarian Epithelial with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Carcinoma, Ovarian Epithelial studies recruiting now, 50 (67%) set no upper age limit and 12 (16%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 500 studies in Carcinoma, Ovarian Epithelial with a site in United States, or all of them as a file.
02

Study summary

This Phase 3 study is designed to compare the efficacy and safety of mirvetuximab soravtansine (MIRV) vs. IC chemotherapy in participants with platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, whose tumors express a high-level of FRα. Participants will be, in the opinion of the Investigator, appropriate for single-agent therapy for their next line of therapy. The FRα positivity will be defined by the Ventana FOLR1 (FOLR1-2.1) CDx assay.

Read the detailed description

Participants will be randomized to either MIRV or IC chemotherapy (paclitaxel, PEGylated liposomal doxorubicin, or topotecan).

03

Conditions studied

  • Epithelial Ovarian Cancer
  • Peritoneal Cancer
  • Fallopian Tube Cancer

Keywords

  • Platinum-resistant
  • Folate-receptor alpha expression
  • Phase 3
  • Antibody-drug conjugate
  • mirvetuximab soravtansine
  • IMGN853
  • Epithelial Ovarian Cancer
  • Peritoneal Cancer
  • Fallopian Tube Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female participants ≥ 18 years of age
  2. Participants must have a confirmed diagnosis of high-grade serious epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
  3. Participants must have platinum-resistant disease:

    1. Participants who have only had 1 line of platinum based therapy must have received at least 4 cycles of platinum, must have had a response (CR or PR) and then progressed between >3 months and ≤ 6 months after the date of the last dose of platinum
    2. Participants who have received 2 or 3 lines of platinum therapy must have progressed on or within 6 months after the date of the last dose of platinum Note: Progression should be calculated from the date of the last administered dose of platinum therapy to the date of the radiographic imaging showing progression. Note: Participants who are platinum- during front-line treatment are excluded
  4. Participants must have progressed radiographically on or after their most recent
  5. Participants must be willing to provide an block or slides, or undergo procedure to obtain a new biopsy using a low risk, medically routine procedure for immunohistochemistry (IHC) confirmation of FRα positivity
  6. Participant's tumor must be positive for FRα expression as defined by the Ventana FOLR1 (FOLR-2.1) CDx assay
  7. Participants must have at least one lesion that meets the definition of by (RECIST) Version 1.1 (radiologically measured by the Investigator)
  8. Participants must have received at least 1 but no more than 3 prior systemic lines of anticancer therapy, and for whom single-agent therapy is appropriate as the next line of treatment:

    1. Adjuvant ± considered one line of therapy
    2. Maintenance therapy (for example, bevacizumab, poly (ADP-ribose) polymerase [PARP] inhibitors) will be considered as part of the preceding line of therapy (that is, not counted independently)
    3. Therapy changed due to toxicity in the absence of progression will be considered as part of the same line (that is, not counted independently)
    4. Hormonal therapy will be counted as a separate line of therapy unless it was given as maintenance
  9. Participant must have an Performance Status (ECOG PS) of 0 or 1
  10. Time from prior therapy:

    1. Systemic antineoplastic therapy (5 half-lives or 4 weeks, whichever is shorter)
    2. Focal radiation completed at least 2 weeks prior to first dose of study drug
  11. Participants must have stabilized or recovered (Grade 1 or baseline) from all prior therapy-related toxicities
  12. Major surgery must be completed at least 4 weeks prior to first dose and have recovered or stabilized from the side effects of prior surgery
  13. Participants must have adequate hematologic, liver and kidney functions defined as:

    1. (ANC) ≥ 1.5 x 10\^9/liter (L) (1,500/microliter [μL]) without granulocyte colony-stimulating factor (G-CSF) in the prior 10 days or long-acting white blood cell (WBC) growth factors in the prior 20 days
    2. count ≥ 100 x 10\^9/L (100,000/μL) without platelet transfusion in the prior 10 days
    3. ≥ 9.0 g/dL without packed red blood cell (PRBC) transfusion in the prior 21 days
    4. Serum creatinine ≤ 1.5 x (ULN)
    5. (AST) and alanine aminotransferase (ALT) ≤ 3.0 x ULN
    6. Serum ≤ 1.5 x ULN (participants with documented diagnosis of Gilbert syndrome are eligible if total bilirubin \< 3.0 x ULN
    7. Serum albumin ≥ 2 grams (g)/deciliter (dL)
  14. Participants or their legally authorized representative must be willing and able to sign the form (ICF) and to adhere to the protocol requirements
  15. Women of (WCBP) must agree to use highly effective method(s) while on study drug and for at least 3 months after the last dose of MIRV or at least 6 months after the last dose of paclitaxel, pegylated liposomal doxorubicin, or topotecan
  16. WCBP must have a negative pregnancy test within 4 days prior to the first dose of study drug

Exclusion criteria

Exclusion Criteria:

  1. Participants with endometrioid, clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of the above histologies, or low-grade or borderline ovarian tumor
  2. Participants with primary platinum- disease, defined as disease that did not respond to (CR or PR) or has progressed within 3 months of the last dose of platinum-containing chemotherapy
  3. Participants with prior wide-field radiotherapy (RT) affecting at least 20% of the bone marrow
  4. Participants with > Grade 1 peripheral neuropathy per (CTCAE) v5.0
  5. Participants with active or chronic corneal disorders, history of corneal transplantation, or active ocular conditions requiring ongoing treatment/monitoring such as uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema, and /or monocular vision
  6. Participants with serious concurrent illness or active infection, including, but not limited to the following:

    1. Active or C infection (whether or not on active antiviral therapy)
    2. (HIV) infection
    3. Active cytomegalovirus infection
    4. Any other concurrent infectious disease requiring IV antibiotics within 2 weeks before starting study drug Note: Testing at screening is not required for the above infections unless clinically indicated
  7. Participants with history of multiple sclerosis or other demyelinating disease and/or Lambert-Eaton syndrome (paraneoplastic syndrome)
  8. Participants with clinically significant cardiac disease including, but not limited to, any one of the following:

    1. Myocardial infarction ≤ 6 months prior to first dose
    2. Unstable angina pectoris
    3. Uncontrolled congestive heart failure ( > class II)
    4. Uncontrolled ≥ Grade 3 hypertension (per CTCAE)
    5. Uncontrolled cardiac arrhythmias
  9. Participants assigned to PLD stratum only: (LVEF) below the institutional limit of normal as measured by echocardiography (ECHO) or multigated acquisition (MUGA) scan
  10. Participants with a history of hemorrhagic or ischemic stroke within six months prior to randomization
  11. Participants with a history of cirrhotic liver disease ( Class B or C)
  12. Participants with a previous clinical diagnosis of non-infectious interstitial lung disease (ILD), including noninfectious pneumonitis
  13. Participants with required use of folate-containing supplements (for example, folate deficiency)
  14. Participants with prior to monoclonal antibodies
  15. Women who are pregnant or lactating
  16. Participants with prior treatment with MIRV or other FRα-targeting agents
  17. Participants with untreated or symptomatic central nervous system (CNS)
  18. Participants with a history of other within 3 years prior to randomization. Note: does not include tumors with a negligible risk for metastasis or death (for example, adequately controlled basal-cell carcinoma or squamous-cell carcinoma of the skin, or carcinoma in situ of the cervix or breast
  19. Prior known hypersensitivity reactions to study drugs and/or any of their
  20. People who are detained through a court or administrative decision, receiving psychiatric care against their will, adults who are the subject of a legal protection order (under tutorship/curatorship), people who are unable to express their consent, and people who are subject to a legal guardianship order
  21. Simultaneous participation in another research study, in countries or localities where this is the health authority guidance
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
453 participants (actual)

Study arms

  • Experimental
    Mirvetuximab Soravtansine

    Participants will receive single-agent mirvetuximab soravtansine (MIRV) at 6 milligrams (mg)/kilogram (kg) adjusted ideal body weight (AIBW) administered intravenously (IV) on Day 1 of every 3-week cycle (Q3W).

    Drug: Mirvetuximab Soravtansine

  • Active comparator
    Investigator's Choice (IC) Chemotherapy

    Participants will receive a dose of IC chemotherapeutic agent calculated using body surface area (BSA). Paclitaxel administered at 80 milligrams/square meter (mg/m\^2) as a 1-hour IV infusion on Days 1, 8, 15, and 22 of a 4-week cycle; or topotecan administered at 4 mg/m\^2 over 30 minutes on Days 1, 8, and 15 of a 4-week cycle. Alternatively, topotecan could be administered at 1.25 mg/m\^2 over 30 minutes on Days 1 to 5 of a 3-week cycle; or pegylated liposomal doxorubicin administered at 40 mg/m\^2 as a 1 mg/minute IV infusion on Day 1 of a 4-week cycle. After Cycle 1, if tolerated, pegylated liposomal doxorubicin could be administered as a 1-hour infusion.

    Drug: Paclitaxel · Drug: Topotecan · Drug: Pegylated liposomal doxorubicin

Interventions

  • Mirvetuximab Soravtansine will be administered per dose and schedule specified in the arm.

    Also known as: MIRV, IMGN853

  • Paclitaxel will be administered per dose and schedule specified in the arm.

  • Topotecan will be administered per dose and schedule specified in the arm.

  • Pegylated liposomal doxorubicin will be administered per dose and schedule specified in the arm.

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

    PFS was defined as the time from randomization until progressive disease (PD) or death whichever occurred first. PD: At least a 20% increase in the sum of the longest diameters (SoD) of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 millimeters (mm). Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

    Time frame: From randomization until PD or death, whichever occurred first (up to approximately 36 months)

Secondary outcomes

  1. Objective Response Rate (ORR), as Assessed by the Investigator Using RECIST v1.1

    ORR was defined as percentage of participants with a confirmed best overall response (BOR) of complete response (CR) or partial response (PR). CR: Disappearance of all target or non-target lesions. All pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least 30% decrease in the sum of the longest diameters (SoD) of target lesions, taking as reference the baseline SoD.

    Time frame: Up to approximately 36 months

  2. Overall Survival Assessed by the Investigator Using RECIST v1.1

    Overall survival was defined as the time from the date of first dose until the date of death from any cause, estimated using the Kaplan-Meier method.

    Time frame: Up to approximately 45 months

  3. Number of Participants Achieving at Least 15 Point Absolute Improvement in the Abdominal/Gastrointestinal (GI) Scale of European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Ovarian Cancer Module 28 (QLQ-OV28)

    The EORTC QLQ-OV28 is specific for ovarian cancer and consists of 28 items assessing abdominal/gastrointestinal symptoms (6 items), peripheral neuropathy (2 items), other chemotherapy side effects (5 items), hormonal symptoms (2 items), body image (2 items), attitudes to disease/treatment (3 items), sexuality (4 items) and 4 other single items. Each scale was scored from 0 to 100 with higher scores on the symptom scales indicating greater symptom burden. Higher scores represent a higher ("better") level of functioning. Presented here are the number of participants achieving at least 15 point absolute improvement at Week 8 or Week 9 in the abdominal/GI scale of the EORTC QLQ-OV28.

    Time frame: Baseline and Week 8 or 9

  4. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence that developed or worsened in severity during the conduct of a clinical study and did not necessarily have a causal relationship to study drug. TEAEs were defined as AEs with an onset date on or after the first dose of study drug, and within 30 days of the last dose of study drug or prior to the start of a new anticancer treatment, whichever occurred first. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Up to approximately 37 months

  5. Duration of Response (DOR) as Assessed by the Investigator Using RECIST v1.1

    DOR was defined as the time from the date of the first response (CR or PR), until the date of PD or death from any cause, whichever occurred first. DOR for participants who have not progressed or died at the time of analysis are censored at the date of their last tumor assessment. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also have demonstrated an absolute increase of at least 5 mm. DOR was estimated using the Kaplan-Meier method.

    Time frame: Up to approximately 34 months

  6. Percentage of Participants With Cancer Antigen 125 (CA-125) Confirmed Clinical Response Per Gynecologic Cancer Intergroup (GCIG) Criteria

    The GCIG CA-125 response was defined as at least 50% reduction in CA-125 levels from baseline. The response must have been confirmed and maintained for at least 28 days.

    Time frame: Baseline up to approximately 36 months

  7. Time to Second Progression-Free Survival (PFS 2)

    PFS 2 was defined as the time from date of randomization until second disease progression or death whichever occurred first.

    Time frame: Up to approximately 44 months

07

Results

Posted Aug 1, 2024

Participant flow

Participant flow — Overall Study
MilestoneMirvetuximab SoravtansineInvestigator's Choice (IC) Chemotherapy
Started227226
Received at least 1 dose of study drug218207
Completed00
Not completed227226
Withdrew: Death161177
Withdrew: Pi discretion11
Withdrew: Lost to follow-up52
Withdrew: Withdrew consent1024
Withdrew: Sponsor decision4418
Withdrew: Other than specified64

Outcome measures

PrimaryProgression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

PFS was defined as the time from randomization until progressive disease (PD) or death whichever occurred first. PD: At least a 20% increase in the sum of the longest diameters (SoD) of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 millimeters (mm). Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

Time frame:
From randomization until PD or death, whichever occurred first (up to approximately 36 months)
Reported as:
Median · months
Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
monthsMirvetuximab SoravtansineInvestigator's Choice (IC) Chemotherapy
Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.15.59 (4.34 to 5.88)3.98 (2.86 to 4.47)
Statistical analysis
  • Mirvetuximab Soravtansine vs Investigator's Choice (IC) Chemotherapy · Log Rank · p = <0.0001 · Cox proportional hazard: 0.63 · 95% CI 0.513 to 0.785
SecondaryObjective Response Rate (ORR), as Assessed by the Investigator Using RECIST v1.1

ORR was defined as percentage of participants with a confirmed best overall response (BOR) of complete response (CR) or partial response (PR). CR: Disappearance of all target or non-target lesions. All pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least 30% decrease in the sum of the longest diameters (SoD) of target lesions, taking as reference the baseline SoD.

Time frame:
Up to approximately 36 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR), as Assessed by the Investigator Using RECIST v1.1
percentage of participantsMirvetuximab SoravtansineInvestigator's Choice (IC) Chemotherapy
Objective Response Rate (ORR), as Assessed by the Investigator Using RECIST v1.141.9 (35.4 to 48.6)15.9 (11.4 to 21.4)
SecondaryOverall Survival Assessed by the Investigator Using RECIST v1.1

Overall survival was defined as the time from the date of first dose until the date of death from any cause, estimated using the Kaplan-Meier method.

Time frame:
Up to approximately 45 months
Reported as:
Median · months
Overall Survival Assessed by the Investigator Using RECIST v1.1
monthsMirvetuximab SoravtansineInvestigator's Choice (IC) Chemotherapy
Overall Survival Assessed by the Investigator Using RECIST v1.116.85 (14.36 to 19.78)13.34 (11.37 to 15.15)
SecondaryNumber of Participants Achieving at Least 15 Point Absolute Improvement in the Abdominal/Gastrointestinal (GI) Scale of European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Ovarian Cancer Module 28 (QLQ-OV28)

The EORTC QLQ-OV28 is specific for ovarian cancer and consists of 28 items assessing abdominal/gastrointestinal symptoms (6 items), peripheral neuropathy (2 items), other chemotherapy side effects (5 items), hormonal symptoms (2 items), body image (2 items), attitudes to disease/treatment (3 items), sexuality (4 items) and 4 other single items. Each scale was scored from 0 to 100 with higher scores on the symptom scales indicating greater symptom burden. Higher scores represent a higher ("better") level of functioning. Presented here are the number of participants achieving at least 15 point absolute improvement at Week 8 or Week 9 in the abdominal/GI scale of the EORTC QLQ-OV28.

Time frame:
Baseline and Week 8 or 9
Reported as:
Count of participants · Participants
Number of Participants Achieving at Least 15 Point Absolute Improvement in the Abdominal/Gastrointestinal (GI) Scale of European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Ovarian Cancer Module 28 (QLQ-OV28)
ParticipantsMirvetuximab SoravtansineInvestigator's Choice (IC) Chemotherapy
Number of Participants Achieving at Least 15 Point Absolute Improvement in the Abdominal/Gastrointestinal (GI) Scale of European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Ovarian Cancer Module 28 (QLQ-OV28)3423
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence that developed or worsened in severity during the conduct of a clinical study and did not necessarily have a causal relationship to study drug. TEAEs were defined as AEs with an onset date on or after the first dose of study drug, and within 30 days of the last dose of study drug or prior to the start of a new anticancer treatment, whichever occurred first. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Up to approximately 37 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsMirvetuximab SoravtansineInvestigator's Choice (IC) Chemotherapy
Number of Participants With Treatment-emergent Adverse Events (TEAEs)211194
SecondaryDuration of Response (DOR) as Assessed by the Investigator Using RECIST v1.1

DOR was defined as the time from the date of the first response (CR or PR), until the date of PD or death from any cause, whichever occurred first. DOR for participants who have not progressed or died at the time of analysis are censored at the date of their last tumor assessment. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also have demonstrated an absolute increase of at least 5 mm. DOR was estimated using the Kaplan-Meier method.

Time frame:
Up to approximately 34 months
Reported as:
Median · months
Duration of Response (DOR) as Assessed by the Investigator Using RECIST v1.1
monthsMirvetuximab SoravtansineInvestigator's Choice (IC) Chemotherapy
Duration of Response (DOR) as Assessed by the Investigator Using RECIST v1.16.93 (5.78 to 8.84)4.44 (4.17 to 5.75)
SecondaryPercentage of Participants With Cancer Antigen 125 (CA-125) Confirmed Clinical Response Per Gynecologic Cancer Intergroup (GCIG) Criteria

The GCIG CA-125 response was defined as at least 50% reduction in CA-125 levels from baseline. The response must have been confirmed and maintained for at least 28 days.

Time frame:
Baseline up to approximately 36 months
Reported as:
Number · percentage of participants
Percentage of Participants With Cancer Antigen 125 (CA-125) Confirmed Clinical Response Per Gynecologic Cancer Intergroup (GCIG) Criteria
percentage of participantsMirvetuximab SoravtansineInvestigator's Choice (IC) Chemotherapy
Percentage of Participants With Cancer Antigen 125 (CA-125) Confirmed Clinical Response Per Gynecologic Cancer Intergroup (GCIG) Criteria58.0 (50.5 to 65.3)30.1 (23.1 to 38.0)
SecondaryTime to Second Progression-Free Survival (PFS 2)

PFS 2 was defined as the time from date of randomization until second disease progression or death whichever occurred first.

Time frame:
Up to approximately 44 months
Reported as:
Median · months
Time to Second Progression-Free Survival (PFS 2)
monthsMirvetuximab SoravtansineInvestigator's Choice (IC) Chemotherapy
Time to Second Progression-Free Survival (PFS 2)11.01 (9.30 to 12.02)7.59 (6.60 to 8.84)

Adverse events

Collected over All-cause mortality and adverse event tables include events reported from the start of safety data collection to the end of the study. The median time on follow-up was 31.1 months and 29.7 months for Mirvetuximab Soravtansine and Investigator's Choice (IC) Chemotherapy, respectively.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mirvetuximab Soravtansine162/227 (71.4%)62/227 (27.3%)212/227 (93.4%)
Investigator's Choice (IC) Chemotherapy177/226 (78.3%)73/226 (32.3%)196/226 (86.7%)
Most frequent serious events
Showing 10 of 100
Most frequent serious events
EventMirvetuximab SoravtansineInvestigator's Choice (IC) Chemotherapy
SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders6/22711/226
INTESTINAL OBSTRUCTIONGastrointestinal disorders5/2276/226
ABDOMINAL PAINGastrointestinal disorders6/2271/226
PLEURAL EFFUSIONRespiratory, thoracic and mediastinal disorders6/2271/226
NEUTROPENIABlood and lymphatic system disorders0/2274/226
ASCITESGastrointestinal disorders4/2272/226
THROMBOCYTOPENIABlood and lymphatic system disorders3/2273/226
SUBILEUSGastrointestinal disorders1/2273/226
DYSPNOEARespiratory, thoracic and mediastinal disorders2/2273/226
VOMITINGGastrointestinal disorders3/2272/226
Most frequent other events
Showing 10 of 53
Most frequent other events
EventMirvetuximab SoravtansineInvestigator's Choice (IC) Chemotherapy
VISION BLURREDEye disorders101/22712/226
ANAEMIABlood and lymphatic system disorders30/22779/226
KERATOPATHYEye disorders78/2274/226
DRY EYEEye disorders73/22715/226
DIARRHOEAGastrointestinal disorders68/22737/226
CATARACTEye disorders67/22728/226
FATIGUEGeneral disorders67/22751/226
ABDOMINAL PAINGastrointestinal disorders65/22735/226
CONSTIPATIONGastrointestinal disorders65/22744/226
NAUSEAGastrointestinal disorders61/22763/226

Baseline characteristics

The intent-to-treat (ITT) population included all participants randomized to the study, regardless of whether or not participants received study treatment (MIRV or IC Chemo).

Age, Continuous
Age, Continuous(years)Mirvetuximab SoravtansineInvestigator's Choice (IC) ChemotherapyTotal
Mean63.3 ± 9.8562.3 ± 9.3062.8 ± 9.58
Sex: Female, Male
Sex: Female, Male(Participants)Mirvetuximab SoravtansineInvestigator's Choice (IC) ChemotherapyTotal
Female227226453
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Mirvetuximab SoravtansineInvestigator's Choice (IC) ChemotherapyTotal
Hispanic or Latino121527
Not Hispanic or Latino177163340
Unknown or Not Reported384886
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Mirvetuximab SoravtansineInvestigator's Choice (IC) ChemotherapyTotal
American Indian or Alaska Native000
Asian282553
Native Hawaiian or Other Pacific Islander000
Black or African American8513
White156145301
More than one race000
Unknown or Not Reported355186
08

Study locations

214 sites
  • University of Alabama at Birmingham (UAB) GYN Oncology
    Birmingham, Alabama 35233, United States
  • Alaska Women's Cancer Care
    Anchorage, Alaska 99508, United States
  • Arizona Oncology Associates, PC - HAL - USOR
    Phoenix, Arizona 85016, United States
  • Mayo Clinic
    Phoenix, Arizona 85054, United States
  • USOR: Arizona Oncology Associates, PC - HOPE
    Tucson, Arizona 85711, United States
  • University of Arizona Cancer Center
    Tucson, Arizona 85719, United States
  • UCLA - JCCC Dept of OBGYN - Women's Health Clinical Research Unit
    Los Angeles, California 90095, United States
  • Hoag Cancer Center
    Newport Beach, California 92663, United States
  • University of California San Francisco
    San Francisco, California 94143, United States
  • Olive View - UCLA Medical Center
    Sylmar, California 91324, United States
  • Kaiser Permanente Oncology Clinical Trials
    Vallejo, California 94589, United States
  • USOR: Rocky Mountain Cancer Centers
    Lakewood, Colorado 80228, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06520, United States
  • Florida Cancer Specialist South Division
    Fort Myers, Florida 33901, United States
  • Mayo Clinic Jacksonville
    Jacksonville, Florida 32224, United States
  • Sarasota Memorial Hospital
    Sarasota, Florida 34239, United States
  • Women's Care Florida / Women's Cancer Associates
    St. Petersburg, Florida 33701, United States
  • Florida Cancer Specialist North Division
    St. Petersburg, Florida 33705, United States
  • Florida Cancer Specialists
    Tallahassee, Florida 32308, United States
  • Florida Cancer Specialist East Division
    West Palm Beach, Florida 33401, United States
  • Memorial University Medical Center
    Savannah, Georgia 31404, United States
  • Hawaii Pacific Health - Kapiolani Medical Center for Women and Children
    Honolulu, Hawaii 96813, United States
  • Illinois Cancer Specialists
    Arlington Heights, Illinois 60005, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Dr. Sudarshan K. Sharma, Ltd.
    Hinsdale, Illinois 60521, United States
  • Community Health Network
    Indianapolis, Indiana 46250, United States
  • University of Kansas Cancer Center
    Westwood, Kansas 66205, United States
  • St. Elizabeth Healthcare
    Edgewood, Kentucky 41017, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40207, United States
  • Ochnser Medical Center Jefferson
    New Orleans, Louisiana 70121, United States
  • WK Physicians Network/Gynecologic Oncology Associates
    Shreveport, Louisiana 771103, United States
  • Holy Cross Hospital
    Silver Spring, Maryland 20902, United States
  • USOR: Maryland Oncology Hematology, P.A.
    Silver Spring, Maryland 20902, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Baystate Medical Center
    Springfield, Massachusetts 01199, United States
  • University of Massachusetts
    Worcester, Massachusetts 01605, United States
  • St. Joseph Mercy Hospital
    Ann Arbor, Michigan 48106, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • USOR: Minnesota Oncology Hematology, PA
    Woodbury, Minnesota 55125, United States
  • HCA Midwest Kansas City/ Sarah Cannon
    Kansas City, Missouri 64132, United States
  • Sletten Cancer Institute
    Great Falls, Montana 59405, United States
  • Center of Hope
    Reno, Nevada 89511, United States
  • The Valley Hospital, Inc
    Ridgewood, New Jersey 07450, United States
  • Holy Name Medical Center
    Teaneck, New Jersey 07666, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • FirstHealth of the Carolinas Outpatient Cancer Center
    Pinehurst, North Carolina 28374, United States
  • USOR: OHC - Oncology_Hematology Care Clinical Trials, Inc.
    Cincinnati, Ohio 45242, United States
  • MetroHealth Medical Center
    Cleveland, Ohio 44109, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Columbus NCORP
    Columbus, Ohio 43215, United States
  • Zangmeister Cancer Center
    Columbus, Ohio 43219, United States
  • Oncology_Hematology Care Clinical Trials, LLC
    Fairfield, Ohio 45014, United States
  • The Ohio State University Wexner Medical Center
    Hilliard, Ohio 43026, United States
  • Stephenson Cancer Center
    Oklahoma City, Oklahoma 73104, United States
  • Oklahoma Cancer Specialists and Research Institute
    Tulsa, Oklahoma 74146, United States
  • USOR: Willamette Valley Cancer Institute and Research Center
    Eugene, Oregon 97401, United States
  • Legacy Gynecologic Oncology
    Portland, Oregon 97210, United States
  • USOR: Northwest Cancer Specialists, P.C.
    Portland, Oregon 97227, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Magee-Women's Hospital-UPMC
    Pittsburgh, Pennsylvania 15213, United States
  • West Penn Hospital
    Pittsburgh, Pennsylvania 15224, United States
  • Women & Infants Hospital of Rhode Island
    Providence, Rhode Island 02905, United States
  • Tennessee Oncology / Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • USOR: Texas Oncology-South Austin
    Austin, Texas 78745, United States
  • USOR: Texas Oncology - Fort Worth Cancer Center
    Fort Worth, Texas 76104, United States
  • University of Texas, Memorial Hermann
    Houston, Texas 77030, United States
  • USOR: Texas Oncology - McAllen South Second
    McAllen, Texas 78503, United States
  • USOR: Texas Oncology - San Antonio
    San Antonio, Texas 78240, United States
  • USOR: Texas Oncology, P.A.
    Sugar Land, Texas 77479, United States
  • USOR: Texas Oncology - The Woodlands, Gynecologic Oncology
    The Woodlands, Texas 77380, United States
  • USOR: Texas Oncology - Tyler
    Tyler, Texas 75702, United States
  • USOR: Texas Oncology, P.A.
    Webster, Texas 77598, United States
  • University of Virginia Health System
    Charlottesville, Virginia 22908, United States
  • USOR: Virginia Cancer Specialists, PC
    Gainesville, Virginia 20155, United States
  • Kadlec Clinic Hematology & Oncology
    Kennewick, Washington 99336, United States
  • West Virginia University- MBRCC
    Morgantown, West Virginia 26506, United States
  • Newcastle Private Hospital
    New Lambton Heights, New South Wales 2305, Australia
  • Prince of Wales Hospital
    Randwick, New South Wales 2031, Australia
  • Monash Health
    Clayton, Victoria 3168, Australia
  • Oncology Clinics Victoria (OCV) - Cabrini Malvern Hospital Location
    Malvern, Victoria 3144, Australia
  • Royal North Shore Hospital
    Saint Leonards, 2065, Australia
  • Burnside War Memorial Hospital - The Brian Fricker Oncology Centre
    Toorak Gardens, 5065, Australia
  • OLV Ziekenhuis
    Aalst, 9300, Belgium
  • AZ Klina
    Brasschaat, 2390, Belgium
  • Universitair Ziekenhuis Antwerpen (UZA) - Borstkliniek
    Edegem, 2650, Belgium
  • AZ St-Lucas
    Ghent, 9000, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Complex Oncology Center
    Burgas, 8000, Bulgaria
  • UMHAT Georgi Stranski
    Pleven, 5800, Bulgaria
  • Acibadem City Clinic Tokuda Hospital
    Sofia, 1407, Bulgaria
  • UMHAT "Sv. Ivan Rilski", EAD, Sofia
    Sofia, 1431, Bulgaria
  • Tom Baker Cancer Centre
    Calgary, Alberta T2N 4N2, Canada
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • The Ottawa Hospital General Campus
    Ottawa, Ontario K1H8L6, Canada
  • Sunnybrook Health Sciences Center
    Toronto, Ontario M4N 3M5, Canada
  • Princess Margaret Cancer Centre - University Health Network
    Toronto, Ontario M5G 2M9, Canada
  • Centre Hospitalier de L'Universite de Montreal
    Montreal, Quebec H2X 0A9, Canada
  • McGill University Health Centre
    Montreal, Quebec H4A 3J1, Canada

Showing the first 100 of 214 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Van Gorp T, Moore KN, Konecny GE, Leary A, Garcia-Garcia Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Caruso G, Klasa-Mazurkiewicz D, Tromp J, Martin LP, Breuer S, Leath CA 3rd, Cibula D, Weroha SJ, Estevez-Garcia P, O'Malley DM, Miller RE, Coffman L, Scandurra G, Berton D, Li L, Zagadailov E, Diver EJ, Tredan O, Hilpert F. Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor alpha-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol. 2025 Apr;26(4):503-515. doi: 10.1016/S1470-2045(25)00021-X. PubMed 40179908 ↗
  • Moore KN, Angelergues A, Konecny GE, Garcia Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estevez-Garcia P, Coffman L, Nicum S, Duska LR, Pignata S, Galvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Mirvetuximab Soravtansine in FRalpha-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169. PubMed 38055253 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Mar 2023, 38 months.

Results were first posted in Aug 2024, 1 year 4 months after primary completion.

Of 33 phase 3 interventional studies under Carcinoma, Ovarian Epithelial, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 110. This study's 38 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2019
First posted
Dec 24, 2019
StartActual
Dec 31, 2019
Primary completionActual
Mar 6, 2023
CompletionActual
Oct 29, 2024
Results first posted
Aug 1, 2024
Last update
Aug 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04209855
Lead sponsor
AbbVie
Collaborators
Gynecologic Oncology Group, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Responsible party
Sponsor
First posted
Dec 24, 2019
Start date
Dec 31, 2019
Primary completion
Mar 6, 2023
Completion
Oct 29, 2024
Results posted
Aug 1, 2024
Last update
Aug 27, 2025

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirvetuximab soravtansine

Start the discussion